Uploaded November 2025 | Updated September 2026, 3 days ago

---

The SOUL trial is changing the way we think about diabetes treatment. In this EASD 2025 TV interview session, Dr. Rodica Busui (Oregon Health & Science University - OHSU) explains how the first oral GLP-1 receptor agonist has demonstrated cardiovascular risk reduction in people with type 2 diabetes.

Learn -how this oral therapy matches the benefits of injectable GLP-1 treatments, works safely alongside SGLT2 inhibitors, and offers new possibilities for personalized diabetes care including earlier treamtnet, improved glucose control, weight management and easier administration for patients.

Discover why the SOUL trial is a landmark step toward more accessible, effective and holistic diabetes managnement.

#easd2025 #diabetesresearch #SOUL #trial #glucosecontrol #type2diabetes #OHSU #diabetesmanagement #endocrinology #medicalinnovation #weightmanagement #diabetescare #cardiovascularrisk #clinicaltrials #diabetesmedication